Search for a trial

Phase 2 Study of the Safety and Efficacy of CORT125134 in the Treatment of Endogenous Cushing*s Syndrome

The primary objective of the study is to assess the safety of CORT125134 in patients with endogenousCushing*s syndrome. The secondary objective of the study is to assess the evidence of reduction incortisol activity following treatment with…

[18F]mFBG PET-CT imaging of pheochromocytoma

This study has been transitioned to CTIS with ID 2024-513622-35-00 check the CTIS register for the current data. The primary objective of this study is to assess the number of detected pheochromocytoma lesions, proved by histology, with [18F]mFBG…

CXCR4-directed [68Ga]Ga-PentixaFor PET/CT vs AVS performance in a diagnoStic randomized Trial Ultimately comparing hypertenSion outcome in primary aldosteronism

This study has been transitioned to CTIS with ID 2024-512628-12-00 check the CTIS register for the current data. Primary objectives-To assess the concordance between [68Ga]Ga-PentixaFor PET/CT and AVS for identification and/or lateralization of APAs…

An Open-Label Extension Study of the Safety of Relacorilant (CORT125134) in the Treatment of the Signs and Symptoms of Endogenous Cushing Syndrome

Primary Objectives: Safety Assessments: Effect of Administration of Relacorilant on: • Incidence of TEAEs (assessed monthly): TEAEs, SAEs, treatment-related TEAEs, TEAEs leading to early discontinuation of study treatment• Clinical laboratory tests…

Titel Engels

Test